Nuvalent price target raised to $80 from $70 at Piper Sandler

Piper Sandler raised the firm’s price target on Nuvalent to $80 from $70 and keeps an Overweight rating on the shares. The firm is pushing back launch timing of NVL-520 to 2026 from 2025, in line with the company’s “OnTarget 2026” operating plan to have the first potential approved product by 2026, the analyst tells investors in a research note.